Dietary SupplementNCT07474753
Coffee Increases Physical and Cognitive Performance Both in Men and Women
A study testing Low Dose Caffeine (LCOF), Moderate Dose Caffeine (MCOF) and High Dose Caffeine (HCOF) in people with Dietary Supplement and Exercise, run by Northumbria University at 1 site in Turkey (Türkiye).
Trial summary
The impact of caffeine habituation on acute responses to different doses of caffeinated coffee has received minimal attention. This study aimed to investigate the effects of different doses of coffee on physical and cognitive performance in men and women with different levels of daily caffeine consumption. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Dietary Supplement, Exercise
- What is being tested?
- Low Dose Caffeine (LCOF), Moderate Dose Caffeine (MCOF) and High Dose Caffeine (HCOF)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 69 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 4 Dec 2020to 20 Mar 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy individuals
- Physically active individuals
- Non-smokers
- Age between 18 and 30 years
- Free from respiratory insufficiency
- Free from cardiovascular disease
- Free from neuromuscular disorders
- Free from musculoskeletal injury within the previous 6 months
Who cannot join
- Diagnosed cardiovascular disease
- Neuromuscular disease
- Current limb injury
- History of limb injury requiring treatment within the previous 6 months
- Chronic respiratory disease or treatment for chronic respiratory conditions
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Ankara University's Department of Sports Science
Ankara
About this study
Official title: Habitual Caffeine Intake Affects the Ergogenicity of Dosing Regimens on Muscular Endurance But Not on Sprint and Cognitive Performance in Men and Women
The impact of caffeine habituation on acute responses to different doses of caffeinated coffee has received minimal attention. This study aimed to investigate the effects of different doses of coffee on physical and cognitive performance in men and women with different levels of daily caffeine consumption. Sixty-nine (35 women) athletes participated in this study, attending 4 experimental visits in a double-blind, randomized, crossover fashion: decaffeinated coffee (PLA), 1.5 mg·kg-1 (LCOF), 3 mg·kg-1 (MCOF) and 6 mg·kg-1 of caffeine (HCOF) from coffee ingestion. Sixty min after coffee consumption, participants performed squat and bench press exercises (1 repetition maximum, 1RM), 60% of 1RM muscular endurance (ME), maximal sprinting, and cognitive performance (CP) was assessed. Participants were allocated into low (LGROUP), moderate (MGROUP), and high (HGROUP) caffeine consumption groups.
- Conditions
- Dietary Supplement, Exercise
- Being tested
- Low Dose Caffeine (LCOF), Moderate Dose Caffeine (MCOF), High Dose Caffeine (HCOF), Placebo (PLA)
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low Dose Caffeine (LCOF)Dietary supplement
Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.12 g·kg-1 of decaffeinated coffee + 0.04 g·kg-1 of caffeinated coffee to achieve 1.5 mg·kg-1 of caffeine intake in LCOF 60-min before the experimental trial.
Moderate Dose Caffeine (MCOF)Dietary supplement
Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.08 g·kg-1 of decaffeinated coffee + 0.08 g·kg-1 of caffeinated coffee to achieve 3 mg·kg-1 of caffeine intake in MCOF 60-min before the experimental trial.
High Dose Caffeine (HCOF)Dietary supplement
Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.16 g·kg-1 of caffeinated coffee to achieve 6 mg·kg-1 of caffeine intake in HCOF 60-min before the experimental trial.
Placebo (PLA)Dietary supplement
Decaffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.16 g·kg-1 of decaffeinated coffee in PLA 60-min before the experimental trial.
| Study group | Role | What they receive |
|---|---|---|
| Low dose caffeine supplementation | Experimental | consuming 0.12 g·kg-1 of decaffeinated coffee + 0.04 g·kg-1 of caffeinated coffee to achieve 1.5 mg·kg-1 of caffeine intake 60-min before the experimental trial. Receives: Dietary Supplement: Low Dose Caffeine (LCOF) |
| Moderate dose caffeine supplementation | Experimental | Consuming 0.08 g·kg-1 of decaffeinated coffee + 0.08 g·kg-1 of caffeinated coffee to achieve 3 mg·kg-1 of caffeine intake 60-min before the experimental trial. Receives: Dietary Supplement: Moderate Dose Caffeine (MCOF) |
| High dose caffeine supplementation | Experimental | Consuming 0.16 g·kg-1 of caffeinated coffee to achieve 6 mg·kg-1 of caffeine intake 60-min before the experimental trial. Receives: Dietary Supplement: High Dose Caffeine (HCOF) |
| Placebo | Experimental | Consuming 0.16 g·kg-1 of decaffeinated coffee 60-min before the experimental trial. Receives: Dietary Supplement: Placebo (PLA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Upper- and Lower-boy muscular endurance
Muscular endurance assessed during bench press and squat exercises using 60% of one-repetition maximum (1RM). Performance expressed as total weight lifted (kg).
Measured: 60 minutes after caffeine or placebo ingestion (during each experimental trial)
Upper- and lower-body strenght
Maximal dynamic strength assessed using one-repetition maximum (1RM) tests in the squat and bench press exercises (kg).
Measured: 60 minutes after caffeine or placebo ingestion (during each experimental trial)
Secondary outcomes (2)
Sprint Performance
Peak power output and mean power output measured during a 15-second Wingate anaerobic test on a cycle ergometer (W/kg).
Measured: 60 minutes after caffeine or placebo ingestion (during each experimental trial)
Cognitive performance
Reaction time (ms) and accuracy measured using a modified arrow flanker task.
Measured: Baseline (before caffeine ingestion) and 60 minutes after caffeine or placebo ingestion.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study start4 Dec 2020
- Primary completion20 Mar 2021
- Study completion20 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dietary SupplementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 69 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northumbria University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Ozcan Esen, Northumbria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07474753
- Sponsor's protocol ID
- İ3-149-20
- Status last verified
- Mar 2026
- First submitted
- 6 Feb 2026
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Habitual Caffeine Intake Affects the Ergogenicity of Dosing Regimens on Muscular Endurance But Not on Sprint and Cognitive Performance in Men and Women
- ClinicalTrials.gov ID
- NCT07474753
- Acronym / sponsor ID
- İ3-149-20
- Conditions
- Dietary Supplement, Exercise
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 69 participants (actual)
- Lead sponsor
- Northumbria UniversityUniversity, hospital or other
- Study start
- 4 Dec 2020 (actual)
- Primary completion
- 20 Mar 2021 (actual)
- Study completion
- 20 Mar 2021 (actual)
- First posted
- 16 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The impact of caffeine habituation on acute responses to different doses of caffeinated coffee has received minimal attention. This study aimed to investigate the effects of different doses of coffee on physical and cognitive performance in men and women with different levels of daily caffeine consumption. Sixty-nine (35 women) athletes participated in this study, attending 4 experimental visits in a double-blind, randomized, crossover fashion: decaffeinated coffee (PLA), 1.5 mg·kg-1 (LCOF), 3 mg·kg-1 (MCOF) and 6 mg·kg-1 of caffeine (HCOF) from coffee ingestion. Sixty min after coffee consumption, participants performed squat and bench press exercises (1 repetition maximum, 1RM), 60% of 1RM muscular endurance (ME), maximal sprinting, and cognitive performance (CP) was assessed. Participants were allocated into low (LGROUP), moderate (MGROUP), and high (HGROUP) caffeine consumption groups.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Low dose caffeine supplementation | Experimental | Dietary Supplement: Low Dose Caffeine (LCOF)consuming 0.12 g·kg-1 of decaffeinated coffee + 0.04 g·kg-1 of caffeinated coffee to achieve 1.5 mg·kg-1 of caffeine intake 60-min before the experimental trial. |
| Moderate dose caffeine supplementation | Experimental | Dietary Supplement: Moderate Dose Caffeine (MCOF)Consuming 0.08 g·kg-1 of decaffeinated coffee + 0.08 g·kg-1 of caffeinated coffee to achieve 3 mg·kg-1 of caffeine intake 60-min before the experimental trial. |
| High dose caffeine supplementation | Experimental | Dietary Supplement: High Dose Caffeine (HCOF)Consuming 0.16 g·kg-1 of caffeinated coffee to achieve 6 mg·kg-1 of caffeine intake 60-min before the experimental trial. |
| Placebo | Experimental | Dietary Supplement: Placebo (PLA)Consuming 0.16 g·kg-1 of decaffeinated coffee 60-min before the experimental trial. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Healthy individuals
- Physically active individuals
- Non-smokers
- Age between 18 and 30 years
- Free from respiratory insufficiency
Key exclusion criteria (5 listed)
- Diagnosed cardiovascular disease
- Neuromuscular disease
- Current limb injury
- History of limb injury requiring treatment within the previous 6 months
- Chronic respiratory disease or treatment for chronic respiratory conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low Dose Caffeine (LCOF)Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.12 g·kg-1 of decaffeinated coffee + 0.04 g·kg-1 of caffeinated coffee to achieve 1.5 mg·kg-1 of caffeine intake in LCOF 60-min before the experimental trial. | Dietary supplement | Low dose caffeine supplementation |
| Moderate Dose Caffeine (MCOF)Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.08 g·kg-1 of decaffeinated coffee + 0.08 g·kg-1 of caffeinated coffee to achieve 3 mg·kg-1 of caffeine intake in MCOF 60-min before the experimental trial. | Dietary supplement | Moderate dose caffeine supplementation |
| High Dose Caffeine (HCOF)Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.16 g·kg-1 of caffeinated coffee to achieve 6 mg·kg-1 of caffeine intake in HCOF 60-min before the experimental trial. | Dietary supplement | High dose caffeine supplementation |
| Placebo (PLA)Decaffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.16 g·kg-1 of decaffeinated coffee in PLA 60-min before the experimental trial. | Dietary supplement | Placebo |
Primary outcome
Upper- and Lower-boy muscular endurance
Time frame: 60 minutes after caffeine or placebo ingestion (during each experimental trial)
Muscular endurance assessed during bench press and squat exercises using 60% of one-repetition maximum (1RM). Performance expressed as total weight lifted (kg).
Upper- and lower-body strenght
Time frame: 60 minutes after caffeine or placebo ingestion (during each experimental trial)
Maximal dynamic strength assessed using one-repetition maximum (1RM) tests in the squat and bench press exercises (kg).
2 secondary outcomes
Sprint Performance
Time frame: 60 minutes after caffeine or placebo ingestion (during each experimental trial)
Cognitive performance
Time frame: Baseline (before caffeine ingestion) and 60 minutes after caffeine or placebo ingestion.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Dietary Supplement
Not yet recruiting
The Effect of a Ginger Formula on Menstrual Health vs a Placebo
Painful Menstruation
Active, not recruiting
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
Overweight, Obesity
Not yet recruiting
Efficacy of MAGNESIO TOTAL on Sleep Quality and Quality of Life in Adults
Sleep Quality, Magnesium Deficiency
Recruiting
The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg Cramps
Poor Sleep Quality, Leg Cramps, Nocturnal
Active, not recruiting
A Study to Evaluate the Effects of a Beef Liver Supplement on Energy, Mood, and Mental Clarity
Fatigue, Low Mood
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low Dose Caffeine (LCOF), Moderate Dose Caffeine (MCOF) and High Dose Caffeine (HCOF) in people with Dietary Supplement and Exercise, run by Northumbria University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Upper- and Lower-boy muscular endurance (time frame: 60 minutes after caffeine or placebo ingestion (during each experimental trial)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.